BioNTech's (BNTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX - Free Report) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $134.00 price objective on the stock.

Several other research firms also recently commented on BNTX. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Citigroup reissued a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Morgan Stanley decreased their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Finally, BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $141.73.

BioNTech Price Performance

BioNTech stock traded up $0.59 during mid-day trading on Thursday, hitting $99.27. 318,170 shares of the company traded hands, compared to its average volume of 917,767. BioNTech has a one year low of $76.53 and a one year high of $131.49. The stock has a market cap of $23.86 billion, a price-to-earnings ratio of -47.23 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a fifty day moving average price of $97.39 and a 200-day moving average price of $108.38.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the business posted $1.90 earnings per share. BioNTech's revenue for the quarter was down 19.5% on a year-over-year basis. On average, equities analysts predict that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Banque Cantonale Vaudoise bought a new position in BioNTech in the 1st quarter worth about $36,000. Jones Financial Companies Lllp increased its position in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Banque Transatlantique SA purchased a new stake in BioNTech in the 1st quarter worth approximately $80,000. Quintet Private Bank Europe S.A. raised its stake in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after acquiring an additional 700 shares during the period. Finally, Allianz SE bought a new stake in BioNTech during the 4th quarter worth approximately $90,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.